Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vismodegib and PDT for multiple basal cell carcinomas
NCT02639117Phase 1Completed
- Sponsor
- University of Arizona
- Start
- Nov 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vismodegib in basal cell carcinoma (BCC), sponsored by University of Arizona. Primary endpoint: Number of participants with treatment related adverse events at 2 years. Started Nov 2015; status: completed.
02
Drugs
vismodegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02639117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639117.